News & Updates

Apalutamide added on to abiraterone acetate, prednisone extends rPFS in mCRPC

12 Mar 2021 by

Adding apalutamide (APA) to abiraterone acetate and prednisone (AAP) significantly extends radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with AAP only, according to the final analysis of the ACIS* trial presented at ASCO GU 2021.

Apalutamide added on to abiraterone acetate, prednisone extends rPFS in mCRPC

12 Mar 2021

HPV screening alone best bet for cervical cancer

11 Mar 2021 by

Among the screening strategies for cervical cancer, stand-alone human papillomavirus (HPV) testing provides a better balance of benefits and harms than co-testing with conventional Papanicolaou (Pap) smear or liquid-based cytology, as shown in the MARZY cohort study.

HPV screening alone best bet for cervical cancer

11 Mar 2021

Adding bemarituzumab to chemo may up survival in advanced FGFR2b+, HER2- gastric cancer

11 Mar 2021 by

Adding bemarituzumab to mFOLFOX6 significantly improved survival outcomes and response rate compared with mFOLFOX6 alone in patients FGFR2b-positive, HER2-negative gastric cancer, according to the FIGHT study presented at the 2021 ASCO GI Cancer Symposium.

Adding bemarituzumab to chemo may up survival in advanced FGFR2b+, HER2- gastric cancer

11 Mar 2021

Back pain, male sex predict vertebral deformity among childhood leukaemia survivors

11 Mar 2021 by

Vertebral deformity is prevalent among survivors of childhood acute lymphoblastic leukaemia (ALL), according to the PETALE Study. Male sex, back pain, and cumulative glucocorticoid dose are all associated with prevalent vertebral deformity.

Back pain, male sex predict vertebral deformity among childhood leukaemia survivors

11 Mar 2021

Sipping tea helps thwart nasopharyngeal carcinoma

11 Mar 2021

Tea drinking has been established as a healthy habit, with its benefits extending to nasopharyngeal carcinoma prevention, according to a study.

Sipping tea helps thwart nasopharyngeal carcinoma

11 Mar 2021

GI cancer patients could continue therapy during COVID-19 pandemic

10 Mar 2021 by

Results of a single-centre study in the UK have suggested that patients receiving systemic anticancer therapy for gastrointestinal (GI) cancers could continue their treatment during the COVID-19 pandemic.

GI cancer patients could continue therapy during COVID-19 pandemic

10 Mar 2021

Chemo continues to benefit UTUC patients, updated POUT analysis shows

10 Mar 2021 by

In an updated analysis of the phase III POUT* trial presented at ASCO GU 2021, peri-operative chemotherapy continued to improve disease-free survival (DFS) compared with surveillance in patients with upper tract urothelial cancer (UTUC).

Chemo continues to benefit UTUC patients, updated POUT analysis shows

10 Mar 2021

Nivolumab + cabozantinib combo offers better QoL in advanced RCC

10 Mar 2021 by

First-line treatment with nivolumab plus cabozantinib (NIVO+CABO) led to significantly better patient-reported quality of life (QoL) outcomes compared with sunitinib in patients with advanced renal cell carcinoma (RCC), according to an exploratory analysis of the CheckMate 9ER* trial presented at ASCO GU 2021.

Nivolumab + cabozantinib combo offers better QoL in advanced RCC

10 Mar 2021

Enfortumab vedotin improves survival in previously treated advanced urothelial carcinoma

09 Mar 2021 by

Enfortumab vedotin improved overall survival (OS) compared with chemotherapy in patients with previously treated, locally advanced or metastatic urothelial carcinoma (UC), according to interim results of the phase III EV-301 study.

Enfortumab vedotin improves survival in previously treated advanced urothelial carcinoma

09 Mar 2021

Concurrent checkpoint inhibitor therapy, radiation feasible in advanced melanoma

09 Mar 2021

In patients with regionally advanced melanoma, concurrent administration of ipilimumab and radiation therapy is safe and beneficial, producing high response rates and converting unresectable disease to operable, as shown in a study.

Concurrent checkpoint inhibitor therapy, radiation feasible in advanced melanoma

09 Mar 2021

News & Updates

Filter by Specialty:

Specialty:

Apalutamide added on to abiraterone acetate, prednisone extends rPFS in mCRPC

Apalutamide added on to abiraterone acetate, prednisone extends rPFS in mCRPC

HPV screening alone best bet for cervical cancer

HPV screening alone best bet for cervical cancer

Adding bemarituzumab to chemo may up survival in advanced FGFR2b+, HER2- gastric cancer

Adding bemarituzumab to chemo may up survival in advanced FGFR2b+, HER2- gastric cancer

Back pain, male sex predict vertebral deformity among childhood leukaemia survivors

Back pain, male sex predict vertebral deformity among childhood leukaemia survivors

Sipping tea helps thwart nasopharyngeal carcinoma

Sipping tea helps thwart nasopharyngeal carcinoma

GI cancer patients could continue therapy during COVID-19 pandemic

GI cancer patients could continue therapy during COVID-19 pandemic

Chemo continues to benefit UTUC patients, updated POUT analysis shows

Chemo continues to benefit UTUC patients, updated POUT analysis shows

Nivolumab + cabozantinib combo offers better QoL in advanced RCC

Nivolumab + cabozantinib combo offers better QoL in advanced RCC

Enfortumab vedotin improves survival in previously treated advanced urothelial carcinoma

Enfortumab vedotin improves survival in previously treated advanced urothelial carcinoma

Concurrent checkpoint inhibitor therapy, radiation feasible in advanced melanoma

Concurrent checkpoint inhibitor therapy, radiation feasible in advanced melanoma